-
Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Objective: This post hoc analysis assessed the benefit-risk of aripiprazole once-monthly 400 mg (AOM 400) as acute and long-term maintenance treatment for patients diagnosed with schizophrenia, based on number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). →
-
Mobile Application-Based Self-Management and Chronic Disease Platform Program for Improved Transitional Care of Older Adults With Diabetes
CONCLUSIONS: The program has the potential to improve transitional care in older adults with diabetes, warranting further promotion. →
-
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters
BACKGROUNDThe relationship between molecular subgroups in clear-cell renal cell carcinoma (ccRCC) and metastatic tropism is poorly understood.METHODSWe analyzed over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 phase II clinical trial, where patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.RESULTSAngiogenic tumors (clusters 1 and 2) had a higher rate of pancreatic (21%… →
-
Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
CONCLUSION: The recombinant EM skin test is safe, well-tolerated, and demonstrates preliminary diagnostic accuracy comparable to IGRAs. By successfully validating the translational utility of the MPT64 (RD2) antigen in a human cohort, this study provides a strong proof-of-concept for the EM skin test as a scalable, specific, and cost-effective immunodiagnostic tool. →
-
Correction: Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
[This corrects the article DOI: 10.3389/fimmu.2026.1780294.]. →
-
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer
CONCLUSIONS: Morning ICI infusions confer a modest but clinically meaningful survival benefit that is absent in chemotherapy controls, supporting a causal chronotherapeutic effect. Scheduling ICIs before noon represents a low-cost, immediately actionable strategy warranting prospective confirmation. →
-
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial
BACKGROUND: Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam. We assessed the efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam versus imipenem-cilastatin in complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. →
-
The specialisation trap: Why your best hire might not look like one
When the candidate in front of you lacks the specific industry experience you need, the default option is not hire them and move onto the next. However, Oliver, Jiayi, Yasaman, Marisa, Paolo, and Muhammad, argue that the managers who build the strongest teams are those willing to look beyond industry labels, and instead assess a… →
-
How Job Design for Disability Improves Work for Everyone
Gary Waters / Ikon Images Disability-related innovations are all around us. Curb cuts in sidewalks, originally designed for wheelchair users, benefit caregivers with strollers, travelers with suitcases, and delivery workers with hand trucks. Automatic doors intended for individuals with mobility impairments are convenient for all. Blurred backgrounds in video calls, standing desks and ergonomic keyboards,… →
-
What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture
CONCLUSIONS: Acetazolamide plus diet gave statistically significant improvements of visual function, papilledema, CSF pressure, and quality of life in patients with IIH with mild visual loss. A maximally tolerated dose up to 4 g/day is recommended. →
